 |
A host of next-gen psoriasis competitors are getting ready to break onto the scene, which means there's not much room for Pfizer's ($PFE) Xeljanz--and the company knows it. Pfizer says it'll "reconsider" its investment in a psoriasis indication, recently rejected by the FDA, after it meets with the agency. "[O]vercoming the issues raised … may be difficult, especially in light of the evolving marketplace," the company said this week. In the meantime, it's also dumping projects to develop Xeljanz in ankylosing spondylitis and Crohn's disease. The company will focus on rheumatoid arthritis, psoriatic arthritis and ulcerative colitis to help get the slow starter up to speed. More from FiercePharmaMarketing